Invex Therapeutics Ltd [ASX:IXC] share price and news 2022

Company Description

Invex Therapeutics Ltd (IXC) is a biopharmaceutical company focused on the repurposing of an approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin.

Invex Therapeutics Ltd belongs to Health Care sector and under industry of Pharmaceuticals. You can get more information about this company via their website: http://www.invextherapeutics.com.

This a small cap company with market cap of 44 millions.

Compared to Market and Sector

The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.

Company PE is less than both sector and market. while On the other hand, Company Earning is less than both sector and market.

Earnings PE PB PE growth
Company 0 0 2.28 0
Market 0.85 22.3 1.99 0.84
Sector 1.7 39.6 5.78 0.26

Dividend Growth Chart

The following chart shows you how ixc dividend grows in the recent years.

No data